Skip to content
Search

Latest Stories

Johnson says he is ready to help India amid Covid surge

UK government is looking to help India with medicines and equipment amid a surging second wave of the coronavirus pandemic in the country.

According to reports, British officials are in talks with India and ministers hope some of the supplies of surplus medical equipment can be send to hospitals there whose capacity has been overwhelmed.


British prime minister Boris Johnson said: “We’re looking at what we can do to help and support the people of India, possibly with ventilators.

“Thanks to the ventilator challenge, the huge efforts of British manufacturers, we’re better able now to deliver ventilators to other countries.

“But also possibly with therapeutics, Dexamethasone, other things, we’ll look at what we can do to help.”

Moreover, the United Kingdom is under pressure to cancel a late order of AstraZeneca doses manufactured in India by Serum Institute of India, as it races to meet the demand of its country.

Is UK going to cancel its order of AstraZeneca vaccine from India? “I am not going to get into details of supplies or deliveries but we remain confident in our supply,” prime minister's official spokesman said.

More For You

pharmacy

The UK spends just 9 per cent of healthcare budgets on medicines while patients face growing access gaps.

iStock

UK calls for new pharmaceutical investment to strengthen life sciences

Highlights

  • UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
  • Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
  • Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.

Investment gap

Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.

Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.

Keep ReadingShow less